Sarepta Therapeutics (SRPT) to Release Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) will release its earnings data after the market closes on Wednesday, August 7th. Analysts expect Sarepta Therapeutics to post earnings of ($1.08) per share for the quarter.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.05) by $0.98. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. The company had revenue of $87.01 million during the quarter, compared to analysts’ expectations of $86.92 million. On average, analysts expect Sarepta Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

SRPT stock traded down $2.72 during mid-day trading on Friday, reaching $145.30. 6,312 shares of the stock traded hands, compared to its average volume of 929,494. The company has a debt-to-equity ratio of 0.35, a current ratio of 12.17 and a quick ratio of 11.15. Sarepta Therapeutics has a 52 week low of $95.21 and a 52 week high of $165.87. The stock has a 50-day simple moving average of $143.89. The company has a market cap of $10.89 billion, a price-to-earnings ratio of -26.89 and a beta of 2.12.

A number of research firms have issued reports on SRPT. ValuEngine upgraded shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, June 28th. Morgan Stanley upped their price objective on shares of Sarepta Therapeutics from $165.00 to $220.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. Evercore ISI assumed coverage on shares of Sarepta Therapeutics in a research report on Thursday, April 11th. They set an “outperform” rating and a $175.00 price objective for the company. Zacks Investment Research raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $130.00 price objective for the company in a research report on Wednesday, May 8th. Finally, HC Wainwright set a $267.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Monday, June 17th. One equities research analyst has rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $206.82.

In other news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director now owns 21,717 shares of the company’s stock, valued at $2,606,040. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 6.60% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Story: Leveraged Buyout (LBO)

Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.